UNLIMITED TURBO SHORT - NOVO-NORDISK B | Real-time Euronext Paris 10:00:02 04/06/2024 pm IST | ||
| 1.71 EUR | -9.52% |
|
| Current month | -10.00% | ||
| 1 month | -42.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 1.71 | -9.52% |
| 03/24/03 | 1.89 | -0.53% |
| 31/24/31 | 1.9 | -4.04% |
| 30/24/30 | 1.98 | -3.88% |
| 29/24/29 | 2.06 | +3.52% |
Real-time Euronext Paris
Last update June 04, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 4P7MB | |
| ISIN | NLBNPNL2N591 |
| Date issued | 02/02/2024 |
| Strike | 1,049 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.51 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.035 € |
|---|---|
| Lowest since issue | 1.66 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
917.3
DKK
Spread / Average Target
-2.02%
- Stock Market
- Certificates
- 4P7MB Certificat
